May 05, 2022 / 09:00AM GMT
Martin Ãmark - Xbrane Biopharma AB - CEO
Thank you very much. Welcome, everybody, to this call, where we're going to present the Q1 report of Xbrane Biopharma. I will start to apologize a little bit for my voice today; maybe sounds like I had a heavy night yesterday, but that's not the case. It's a pollen allergic reaction, so apologies for that. But we'll try to do the best out of this call anyway.
So I guess I'll start here with the reminder on our portfolio of Biosimilar candidates we're working on. We have actually come out Lucentis biosimilar candidate, which is currently in the registration phase. We submitted the file to EMA in September last year and to FDA in March this year. And we're currently going through the regulatory processes to try to get towards an approval in Europe during the latter part of this year and then in US most likely Q1 next year.
We have Xcimzane, our biosimilar candidates, which we partner up with Biogen earlier this year. We are very happy with that arrangement and having Biogen as a partner. And then, we're currently going through a tech-transfer in
Q1 2022 Xbrane Biopharma AB Earnings Call Transcript
May 05, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers